PeproMene Bio
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
15375 Barranca Pkwy Ste A211, Irvine, Ca...Phone Number
(949) 418-8860Website
www.pepromenebio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About PeproMene Bio
PeproMene Bio, Inc is a clinical-stage biotech company in Irvine, California. The company is committed to developing novel therapies to treat cancers and immune disorders. The company's BAFFR CAR-T therapy program is based on a novel antibody targeting the B-cell Activating Factor Receptor (BAFF-R) discovered by Dr. Larry Kwaks team at MD Anderson Cancer Center, Houston, Texas, and City of Hope National Medical Center, Duarte, California.Explore more
PeproMene Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PeproMene Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at PeproMene Bio
Click to see if PeproMene Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once PeproMene Bio has new funding data
Check out if PeproMene Bio is spiking on competitors!
Earning: See what the market has to say on PeproMene Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if PeproMene Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when PeproMene Bio launches new products
PeproMene Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at PeproMene Bio
Find 2 more new buyers
Compare Similar Companies to PeproMene Bio
Compare insights from companies similar to PeproMene Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PeproMene Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PeproMene Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PeproMene Bio.
PeproMene Bio financials insights
Gather financial insights about PeproMene Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$11M
PeproMene Bio Tech Stack
A closer look at the technologies used by PeproMene Bio
See more technologies
PeproMene Bio News & Media
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ -- PeproMene Bio, Inc. today announced the publication in The Lancet, one of the world's leading medical journals, of results from its Phase 1 clinical trial evaluating PMB-CT01, the company's first-in-class BAFF-R-targeted CAR T-cell therapy, in...PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
IRVINE, Calif., May 28, 2026 /PRNewswire/ -- PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy, have been selected for an oral...PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
IRVINE, Calif., May 28, 2026 /PRNewswire/ -- PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy, have been selected for an oral...PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PeproMene Bio
Sign Up For FreeTo access detailed company insights
PeproMene Bio, Inc is a clinical-stage biotech company in Irvine, California. The company is committed to developing novel therapies to treat cancers and immune disorders. The company's BAFFR CAR-T therapy program is based on a novel antibody targeting the B-cell Activating Factor Receptor (BAFF-R) discovered by Dr. Larry Kwaks team at MD Anderson... Read More
